Floatz logo

Synthetic Mva-Based Sars-Cov-2 Vaccine Geo-Cm04S1

Plasma Cell Myeloma

GeoVax, Inc.vaccinePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

497 Active assets in the Plasma Cell Myeloma cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Hyaluronidase fihj
Massachusetts General Hospital
Phase 4BBB
Inno-206
University of Arkansas
Phase 3BBB
Busulphan
M.D. Anderson Cancer Center
Phase 4BBB
Filanesib
PETHEMA Foundation
Phase 2BBB

View all 50 →

Same molecule, other indications

Synthetic Mva-Based Sars-Cov-2 Vaccine Geo-Cm04S1 is also rated in:

COVID-19Dormant
CCC
Indicative ·
53 / 100
View asset →
hematopoietic and lymphoid system neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →
leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →